Financiere de Tubize (LTS:0D53) Growth Rank : 0 (As of Jun. 09, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Growth Rank?

Financiere de Tubize has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Financiere de Tubize Growth Rank Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Financiere de Tubize (LTS:0D53) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

TUB:Belgium

Address

Allée de la Recherche, 60, Brussels, BEL, 1070

Website

https://www.financiere-tubize.be

Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (LTS:0D53) Headlines

No Headlines